Precision Medicine in Bladder Cancer

Speaker Date: May 6, 2022

Dr. Milowsky will discuss research he has done in developing novel therapies for patients with urological malignancies and in outcomes for bladder cancer:

  1. Review bladder cancer biology including genomics toward the development of targeted therapies in bladder cancer
  2. Discuss the failures and successes of precision medicine approaches with targeted therapies in bladder cancer
  3. Review the current landscape and future directions of targeted therapy in bladder cancer

On-Demand Streaming Video

On-Demand Streaming Audio

Click below to view presentation (PDF)

Dr Matt Milowsky
UNC, Lineberger Comprehensive Cancer Center


Matthew I. Milowsky, MD, FASCO
I am a medical oncologist, clinical/translational researcher and Vice Chief of Research and Section Chief of Genitourinary Oncology in the Division of Oncology at the University of North Carolina in Chapel Hill.  My research focuses on the development of novel therapies for patients with urologic malignancies. More broadly, I have led and participated in organizations and committees focused on the development of an infrastructure and funding mechanisms for bladder cancer-related research which has been historically underfunded.

More recently, I have been involved in bladder cancer-related outcomes research. My clinical expertise is in genitourinary cancers.

George Gabriel and Frances Gable Villere Distinguished Professor of Bladder and Genitourinary Cancer Research
Vice Chief for Research, Division of Oncology
Vice Chief for Education, Division of Oncology
Section Chief, Genitourinary Oncology
Co-Director, Urologic Oncology Program